Ark 'extends runway until 2013' amid further restructuring
This article was originally published in Scrip
Executive Summary
Ark Therapeutics, the UK firm that suffered a catastrophic setback in December last year when the CHMP rejected its gene therapy candidate Cerepro (sitimagene ceradenovec) for the treatment of brain cancer in Europe, believes it has come up with a strategy that will extend its cash runway until 2013.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.